Interpretation of hepatitis serology
What it is
Hepatitis B serology is read from three tests taken together: HBsAg, anti-HBs and anti-HBc. When anti-HBc is read as IgM or IgG, and HBeAg, anti-HBe and HBV DNA are added, the same three tests give a wider picture that also separates the phases of chronic infection. Chronic hepatitis B infection is defined as persistent detection of HBsAg for more than 6 months after initial exposure to the virus.
How it is diagnosed
Read together, the results run like this.
- Susceptible and non-immune: HBsAg negative, anti-HBc negative, anti-HBs negative.
- Acutely infected: HBsAg positive, anti-HBc positive with IgM anti-HBc positive, anti-HBs negative.
- Chronically infected: HBsAg positive, anti-HBc positive with IgM anti-HBc negative, anti-HBs negative.
- Immune due to natural infection: HBsAg negative, anti-HBc positive as IgG, anti-HBs positive.
- Immune due to hepatitis B vaccination: HBsAg negative, anti-HBc negative, anti-HBs positive.
- Anti-HBc positive alone, with HBsAg and anti-HBs both negative: the interpretation is unclear, with four possibilities, which are resolved infection and this is the most common, a false-positive anti-HBc so the patient is susceptible, low level chronic infection with an HBsAg too low to detect, and resolving acute infection where anti-HBs has not developed yet.
Adding the rest of the panel separates the chronic phases. Acute hepatitis B, and occasionally reactivation of chronic hepatitis B, gives HBsAg positive, IgM anti-HBc positive, HBeAg positive and HBV DNA above 20,000. Resolved previous infection gives anti-HBs and IgG anti-HBc positive with undetected DNA, and immunity from previous vaccination gives anti-HBs alone with undetected DNA. The chronic hepatitis B inactive carrier state gives HBsAg and IgG anti-HBc positive with anti-HBe positive and DNA under 20,000. HBeAg-positive chronic hepatitis B gives HBeAg positive with DNA above 20,000, and HBeAg-negative chronic hepatitis B gives anti-HBe positive with DNA above 10,000. That same source gives two HBV DNA numbers for HBeAg-negative chronic hepatitis B: above 10,000 U/mL where the results are interpreted, and at least 2,000 U/L where treatment is recommended. Both stand as written there, and neither is preferred over the other.
A fifth possibility is named for that same anti-HBc positive alone pattern: the person may be distantly immune, with a test not sensitive enough to detect a very low level of anti-HBs in serum.
Three worked cases show how the pattern is used:
- HBsAg positive with anti-HB core IgM positive, in a man with jaundice, tender hepatomegaly and ALT 900 and AST 900 against a normal below 40, is acute hepatitis B infection.
- HBsAg positive with HBcAb IgG positive and HBeAg positive, and anti-HBs negative, in a woman with jaundice and elevated liver enzymes, is chronic hepatitis B infection.
- HBsAb positive with anti-HBc IgG positive, and HBeAg and HBsAg both negative, is previous infection, not vaccination and not acute or chronic infection.
How it is treated
The serology decides who is treated. Treatment is recommended for a patient with acute liver failure or cirrhosis, for infection in the immune-active phase, meaning HBeAg positive chronic hepatitis B with ALT at least 2 times ULN and HBV DNA at least 20,000 U/L, and for infection in the reactivation phase, meaning HBeAg negative chronic hepatitis B with ALT at least 2 times ULN and HBV DNA at least 2,000 U/L. Treatment usually consists of entecavir or tenofovir, which are preferred, while peg-interferon is rarely used. Infection in the immune-tolerant or inactive carrier phases is not treated, because these are infection and not hepatitis. Read the other way round, HBeAg positive by itself is not a reason to treat. The immune-active phase that is treated is HBeAg positive chronic hepatitis B with the raised ALT and the high HBV DNA alongside it, and without those two the patient sits in the immune-tolerant or the inactive carrier phase and is not treated.
The mother's serology also decides what her baby receives. All pregnant women are offered screening for hepatitis B. Babies born to mothers who are chronically infected, or who had acute hepatitis B during pregnancy, should receive a complete course of vaccination together with hepatitis B immunoglobulin: the first dose of vaccine soon after birth, and, when the mother is surface antigen positive, 0.5 millilitres of hepatitis B immunoglobulin within 12 hours of birth, followed by a further vaccine dose at 1-2 months and at 6 months. Oral antiviral treatment such as lamivudine in the latter part of pregnancy is still being evaluated, and there is little evidence that caesarean section reduces vertical transmission rates.